Key result
Cancer treatments such as anthracyclines, VEGFi, and immune checkpoint inhibitors induce various cardiotoxicities, highlighting the need for preventative strategies and further mechanistic research.
Why the study?
Gaps in knowledge remain regarding optimal strategies for the detection and treatment of cancer treatment-associated cardiotoxicity.
This review highlights the biological mechanisms of cancer treatment-induced cardiotoxicity and identifies critical gaps in knowledge regarding risk characterization and cardioprotective strategies.
While many strides have been made in the multidisciplinary science of Cardio-Oncology, gaps in knowledge remain despite these advances to identify optimal strategies of detection and treatment of cancer treatment-associated cardiotoxicity. Many opportunities are available for advocates from all avenues of the field to transform cardio-oncology from a reactionary to a preventative science.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) conducted a review in Cancer treatment-induced cardiac toxicity. Cancer treatments was evaluated. Cancer treatments such as anthracyclines, VEGFi, and immune checkpoint inhibitors induce various cardiotoxicities, highlighting the need for preventative strategies and further mechanistic research.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: